Becton, Dickinson and Company (NYSE:BDX) Receives $180.29 Average PT from Analysts

Becton, Dickinson and Company (NYSE:BDX) has earned an average recommendation of “Hold” from the sixteen research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $180.2857.

A number of brokerages recently commented on BDX. Stifel Nicolaus lowered their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a report on Monday, July 6th. Zacks Research raised Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research report on Friday, April 10th. Argus dropped their price objective on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a report on Monday, March 23rd. Finally, Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research report on Tuesday, April 14th.

Becton, Dickinson and Company Stock Up 3.2%

Shares of Becton, Dickinson and Company stock opened at $159.85 on Friday. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $187.35. The company has a market capitalization of $44.05 billion, a P/E ratio of 40.47, a P/E/G ratio of 10.96 and a beta of 0.21. The company has a 50 day moving average of $148.81 and a 200 day moving average of $166.44.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same period in the prior year, the firm posted $3.35 EPS. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, research analysts forecast that Becton, Dickinson and Company will post 12.62 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were issued a dividend of $1.05 per share. The ex-dividend date of this dividend was Tuesday, June 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.6%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Insider Activity at Becton, Dickinson and Company

In other news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,188 shares of company stock valued at $765,120 in the last 90 days. Insiders own 0.40% of the company’s stock.

Hedge Funds Weigh In On Becton, Dickinson and Company

Large investors have recently bought and sold shares of the stock. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $25,000. Steph & Co. grew its stake in Becton, Dickinson and Company by 95.6% during the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after buying an additional 65 shares during the last quarter. SHP Wealth Management purchased a new position in Becton, Dickinson and Company during the 4th quarter worth approximately $26,000. Meeder Asset Management Inc. increased its position in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 102 shares during the period. Finally, Main Street Group LTD purchased a new stake in Becton, Dickinson and Company in the first quarter valued at approximately $29,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.